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INTRODUCTION
Brief periods of sublethal ischemia can protect tissues from a subsequent, more severe, ischemia-reperfusion (I/R) insult. This phenomenon of ''ischemic preconditioning'' was first observed in experimental models of myocardial infarction (MI) (Murry et al., 1986) and later in coronary heart disease patients (Kloner et al., 1995) . Patients who have angina (ischemic cardiac chest pain) within 48 hr before a MI have better outcomes than patients who do not experience preceding angina. Subsequent studies with animals showed that ischemia in one coronary artery territory could protect myocardium perfused by another coronary artery (Przyklenk et al., 1993) , and coronary effluent from an ischemic heart can protect a naive acceptor heart ex vivo (Dickson et al., 1999) . Remarkably, ischemia to a non-cardiac organ also protects the heart at a distance (Gho et al., 1996) . Some, but not all, human clinical trials showed that inducing arm ischemia improved outcomes after coronary artery interventions associated with iatrogenic cardiac ischemia (Davies et al., 2013; Hausenloy et al., 2015; Meybohm et al., 2015; Thielmann et al., 2013) . Many RIPC mechanisms have been proposed, including both humoral and neural mechanisms (Przyklenk, 2013) .
The hypoxia-inducible factor (HIF) transcription factor, which consists of a labile a subunit and a stable b subunit, accumulates during hypoxia and activates genes whose products promote cellular survival under ischemic conditions. The HIFa subunit is regulated through prolyl hydroxylation by a-ketoglutarate (aKG)-dependent dioxygenases known as EGLNs (also called PHDs). Of the three EGLN paralogs, EGLN1 is the primary regulator of HIFa (Kaelin and Ratcliffe, 2008) . Hydroxylated HIFa is bound by the von Hippel Lindau (VHL) tumor suppressor protein, which marks HIFa for degradation. EGLNs require O 2 , and HIFa hydroxylation is thus impaired when O 2 is limited, allowing HIFa accumulation. In sum, EGLNs act as ''O 2 sensors'' in metazoans and coordinate cellular responses that promote adaptation to hypoxia and ischemia (Kaelin and Ratcliffe, 2008) .
Cardiac-specific Egln1 inactivation during late embryogenesis protects adult mice from MI after permanent coronary artery occlusion (Hö lscher et al., 2011) . Similarly, mice homozygous for a hypomorphic Egln1 allele have less myocardial damage after I/R than Egln1 +/+ mice (Hyvä rinen et al., 2010) . Conversely, both local and remote preconditioning are attenuated in Hif1a +/À mice (Cai et al., 2008 (Cai et al., , 2013 . Collectively, these results support that HIF protects the heart during acute MI. However, chronic manipulation of HIF causes adaptations, such as increased angiogenesis and decreased mitochondria, that might be irrelevant to therapies aimed at acutely modulating the HIF response in patients with acute myocardial ischemia and impending MI (Huang et al., 2008) . Moreover, a recent report challenged the conclusion that HIF1a is required for RIPC (Kalakech et al., 2013) .
Others have acutely inactivated Egln at the time of experimental MI. The pharmacological prolyl hydroxylase inhibitors, FG0041, GSK360, and 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate (ICA) have been shown to be cardioprotective in rodents (Bao et al., 2010; Nwogu et al., 2001; Vogler et al., 2015) . However, these drugs might inhibit other a-ketoglutarate (aKG)-dependent dioxygenases in addition to the Eglns. Indeed FG0041 was initially tested in this setting because it inhibits the collagen prolyl hydroxylases and only later shown to inhibit the Eglns (Nwogu et al., 2001) . Several groups reported ischemic cardioprotection in mice after intraperitoneal (i.p.) (Natarajan et al., 2006) or intraventricular (Eckle et al., 2008) injection of naked Egln1 siRNAs or intramyocardial injection of a plasmid encoding an Egln1 shRNA (Huang et al., 2008) . Although these interventions reportedly induced HIF, the bioavailability of small interfering RNAs (siRNAs) and plasmids delivered in this way is suspect. Moreover, it was later revealed that the Egln1 siRNA used in one of these studies targeted a collagen prolyl hydroxylase rather than Egln1, raising questions about specificity (Natarajan et al., 2006) . Finally, a recent study reported that intramuscular injection of an adenovirus encoding HIF1a acutely protected the heart at a distance (Cai et al., 2013) .
RESULTS

Chronic Egln1 Inactivation in Cardiomyocytes Protects against I/R Injury
We used genetic and pharmacological tools to probe the role of Egln1 and HIF in local and remote ischemic preconditioning. Adult mice in which Egln1 has been deleted in the heart at $E12.5 experience less myocardial damage after permanent occlusion of the left anterior descending (LAD) coronary artery than do control mice, implying that Egln1 plays a cardiac-intrinsic role in cardioprotection (Hö lscher et al., 2011) . To ask whether this is also true in an ischemia-reperfusion (I/R) model, which more closely mimics myocardial injury during clinical MI, we crossed mice with a conditional (floxed or ''F'') Egln1 allele with a mouse strain expressing Cre recombinase under the control of the cardiac-specific alpha myosin heavy chain (MHC) promoter (Agah et al., 1997) . We confirmed inactivation of Egln1 in the heart, but not skeletal muscle, liver, and kidney, in Egln1 F/F ;MHC-Cre mice ( Figure S1A ). As expected, heart-specific Egln1 inactivation induced HIF target genes ( Figure S1B ). Moreover, cardiac-specific Egln1 inactivation was cardioprotective in mice subjected to cardiac I/R injury ( Figure S1C ) and in isolated hearts in a Langendorff model of global myocardial ischemia, as reflected by a faster recovery (lowering) of end-diastolic pressures compared to control mice ( Figure S1D ). Therefore, chronic Egln1 inactivation confers cardiac-intrinsic protection against both permanent and transient cardiac ischemia.
Acute Systemic Egln1 Inactivation Protects the Heart against I/R Injury We next tested an Egln inhibitor, FG-4497 (Fibrogen) (Laitala et al., 2012; Robinson et al., 2008) , in the same cardiac I/R injury models. We first confirmed that FG-4497 induced HIF1a in HL-1 cardiomyocytes ( Figure 1A ) and inhibited Egln in vivo as determined by imaging mice that ubiquitously express a HIF1a-luciferase fusion reporter (Safran et al., 2006 ) ( Figure 1B) . Notably, FG-4497 stabilized HIF1a and induced HIF target genes in the heart ( Figures 1C and 1D ). Pretreatment with FG-4497 decreased cardiac injury after I/R in the Langendorff model ( Figure 1E ) and decreased MI size in mice subjected to LAD occlusion/release in vivo by $30% ( Figure 1F ). Importantly, from a clinical perspective, FG-4497 treatment at the time of reperfusion also substantially reduced infarct sizes ( Figure 1G ). Next, we used Egln1 F/F ;Cre ER mice that ubiquitously express a tamoxifen (TAM)-activatable Cre ER fusion protein (Minamishima et al., 2008) . Giving such mice TAM for 3 days significantly decreased Egln1 mRNA levels in the heart, kidney, and skeletal muscle compared to TAM-treated Egln1
;Cre ER mice (Figure 2A) and induced HIF1a protein ( Figure 1C ) and HIF-responsive mRNAs in the heart ( Figure 2B ). Acute, systemic, inactivation of Egln1 decreased myocardial injury in the Langendorff I/R model ( Figure 2C ) and decreased MI size in mice subjected to cardiac I/R in vivo compared to TAM-treated Egln1
;Cre ER control mice ( Figure 2D ). Consistent with Egln1 being the relevant target of FG-4497, the effects of the combined Egln1 gene deletion and pharmacologic Egln inhibition were subadditive ( Figure 2E ). Therefore, acute systemic Egln1 inactivation protects against cardiac I/R injury.
Skeletal Muscle Egln1 Deletion Confers Remote Cardiac Ischemic Protection
Protection against cardiac I/R injury after systemic Egln1 loss could reflect a cell-autonomous effect in cardiomyocytes, a non-cell autonomous ''remote'' effect on the heart, or both. To explore non-cell autonomous effects, we made mice in which Egln1 could be conditionally inactivated specifically in skeletal muscle. Egln1 F/F and Egln1 +/+ mice were crossed with mice expressing a TAM-dependent Cre ER transgene driven by a skeletal muscle-specific promoter (human alpha actin; HSA-Cre-ER T2 ) (Schuler et al., 2005 Figure 3A ), decreased Egln1 protein ( Figure S2B ), increased HIF1a protein ( Figure S2C ), or increased HIF-responsive mRNAs ( Figures S2D and S2E ). We next asked whether Egln1 deletion in the skeletal muscle can protect the heart at a distance. TAM-treated Egln1 2003), which might protect the heart by increasing nitric oxide production and decreasing afterload. We did not, however, detect differences in blood pressures between TAM-treated Egln1 ;HSA-Cre-ER T2 mice (Figure S2F) , nor alterations of blood nitrite levels ( Figure S2G ) (Coulet et al., 2003) . These data show that Egln1 inactivation in skeletal muscles confers remote ischemic cardioprotection.
Remote Ischemic Protection by Skeletal Muscle Egln1 Gene Deletion Is Mediated by a Humoral Factor
It is debated whether an intact peripheral nervous system, a soluble humoral factor, or both are required for RIPC (Przyklenk, 2013) . To ask whether a humoral factor mediates RIPC in mice with skeletal muscle-specific Egln1 deletion, we performed a parabiosis experiment. See Figure S1 .
ner). The donor mice were given TAM for 5 days, and 5 days later the recipient mice were subjected to cardiac I/R injury. Evan's blue dye injected 2 days later confirmed shared circulation in both types of pairings ( Figure 3E ). Genotyping confirmed Egln1 deletion specifically in the skeletal muscle of TAM-treated Egln1 Figure 3F ). These data argue that a humoral factor mediates RIPC after Egln1 deletion in skeletal muscle.
Egln1 Inactivation Alters Circulating Tryptophan Metabolites
To look for circulating cardioprotective factors that were upregulated after skeletal muscle deletion of Egln1, we profiled serum cytokines in TAM-treated Egln1 F/F ;HSA-Cre-ER T2 and Egln1
; HSA-Cre-ER T2 mice. None of the 144 cytokines profiled were upregulated >10% after Egln1 loss in skeletal muscle (Figure S3A) . In particular, we did not detect changes in the levels of IL-10 and EPO, which have previously been implicated in RIPC (Cai et al., 2003 (Cai et al., , 2013 ) ( Figure S3B ). In addition, pretreatment with a JAK1/2 inhibitor (Ruxolitinib), which blocks signaling by many cytokine receptors, did not abrogate RIPC in our model ( Figure S3C ). We concluded that the humoral mediator of RIPC in our model was not one of the cytokines examined or a cytokine that signals through JAK1/2. Next, we analyzed gene expression profiles in skeletal muscles from TAM-treated Egln1 F/F ;HSA-Cre-ER T2 and Egln1 +/+ ; HSA-Cre-ER T2 mice and compared differentially regulated genes to a published list of genes predicted to encode secreted proteins (Wu et al., 2010) . Forty-one genes were differentially expressed in the skeletal muscles from TAM-treated Egln1 F/F ;HSA-Cre-ER T2 (q < 0.1), seven of which encode proteins predicted to be secreted (Natarajan et al., 2006; Wu et al., 2010) . Real-time PCR confirmed upregulation of two of these seven mRNAs, PLAC9 and LYPD1 ( Figure S3D ). Relatively little is known of the biologic function of PLAC9 and neither gene, to our knowledge, is known to encode circulating polypeptides. We next looked for a potential small molecule mediator(s) of cardioprotection. Blood was collected from TAM-treated
Egln1
F/F ;HSA-Cre-ER T2 and Egln1 +/+ ;HSA-Cre-ER T2 mice, and serum and plasma metabolites were profiled by liquid chromatography-mass spectrometry (LC-MS). Among the metabolites with statistically significant differences were various tryptophan (TRP)-related metabolites ( Figure 4A ). To narrow the list of possible mediators of remote cardiac I/R protection, we did an orthogonal experiment by profiling selected serum metabolites in WT mice given FG-4497 or vehicle ( Figure 4B ). We hypothesized that the cardioprotective mediator(s) would be induced by both genetic and pharmacological Egln1 inhibition, that systemic Egln1 inhibition might alter levels of the metabolite(s) of interest to an even greater extent than skeletal muscle deletion of Egln1, and that the cardioprotective metabolite(s) would be induced rapidly by FG-4497 since FG-4497 protected hearts even when administered after ischemic injury ( Figure 1G ). Strikingly, we observed significant changes in circulating TRP metabolites 10 min after FG-4497 treatment ( Figure 4B) . Quad. Heart Quad. Heart Quad. Heart Quad. Figure S2 .
The Tryptophan Metabolite Kynurenic Acid Mediates Remote Ischemic Protection after Egln1 Inactivation
We focused on the TRP metabolite kynurenic acid (KYNA) as a possible cardioprotective agent because KYNA is tissue protective in models of cerebral and renal injury (Germano et al., 1987; Pundir et al., 2013; Zwilling et al., 2011) . KYNA production from TRP is regulated by a rate-limiting pyrolase TRP dioxygenase (TDO) in the liver or indoleamine 2,3 dioxygenase (IDO) in peripheral tissues, as well as by aKG-dependent transamination performed by kynurenine transaminases (KAT) ( Figure 4C ) (Agudelo et al., 2014) . We confirmed that the mass spectrometry ion counts we obtained for serum KYNA and aKG in mice were in the linear ranges for their respective assays and consistent with serum concentrations of $5 mM and $50 mM, respectively, in untreated WT mice ( Figures S3E and S3F ). To ask whether KYNA was needed for cardiac I/R protection after skeletal muscle Egln1 deletion, TAM-treated Egln1 F/F ; HSA-Cre-ER T2 and Egln1 +/+ ;HSA-Cre-ER T2 controls were given 1-methyl tryptophan (1MT), a reversible inhibitor of both TDO and IDO, before cardiac I/R injury. 1-MT partially abrogated the protection caused by skeletal muscle deletion of Egln1, but did not affect MI sizes in control animals ( Figure 4D ). Conversely, pretreatment of WT mice with KYNA (Andiné et al., 1988) or the KYNA mimetic L689,560 decreased MI size compared to vehicle-treated mice ( Figures 4E and 4F ). Cardioprotection by KYNA appeared to be heart-autonomous, as addition of KYNA to the perfusate of isolated hearts improved ischemia tolerance (E) MI size after cardiac I/R injury in WT mice pretreated with 100 ng KYNA or Veh. i.p. 2 hr before and 2 hr after in vivo cardiac I/R. Data shown are means ± SEM, n = 16 vehicle, n = 14 KYNA. *p < 0.05, Student's t test. (F) MI size after cardiac I/R injury in WT mice given 40 mg/kg KYNA mimetic L689,560 or Veh. i.p. immediately before I/R injury. Data shown are means ± SEM, n = 3 per group. *p < 0.05, Student's t test. (G) LVEDP in Langendorff assays after global I/R injury, with or without 100 nM KYNA present in the perfusate. Data shown are mean pressures ± SEM, n = 10 KYNA group and n = 9 control group. **p < 0.01, Student's t test. See also Figure S3 .
in Langendorff assays ( Figure 4G ). These data argue that KYNA is necessary and sufficient for remote cardiac ischemic protection following Egln1 inhibition.
Egln1 Inhibition Generates KYNA via Altered Systemic aKG Metabolism KYNA was not induced by inactivating Egln1 in various cell culture models ( Figure S4A ) and mRNAs linked to TRP metabolism were not induced in skeletal muscle after inactivating Egln1 (Figure S4B) , suggesting that the increased KYNA observed after Egln1 inactivation in skeletal muscle in vivo was indirect and non-cell autonomous. In order to determine the organ(s) producing KYNA in our model, mice were infused with U-13 C-TRP and then given FG-4497 ( Figure S4C ). Newly formed U-13 C-KYNA was detected in the serum, liver, kidneys, and lung, but not in skeletal muscle ( Figure 5A ). We concluded that KYNA is made by a tissue other than muscle after Egln1 inactivation in skeletal muscle.
Hepatic KYNA production was intriguing because the TRP metabolites n-methylnicotinamide (NMN) and niacinamide (NAM), which can be made only by the liver and the kidney, were among the serum metabolites downregulated by skeletal muscle Egln1 loss ( Figure 4A) . Moreover, our U- Figure S4 .
confirmed conversion of TRP to NMN and NAM in the liver and not the kidney (data not shown). Upregulation of circulating KYNA combined with downregulation of NMN and NAM suggested altered hepatic TRP metabolism after Egln inhibition ( Figure 4C ).
How might targeting Egln-via systemic FG-4497 administration or skeletal muscle deletion of Egln1-regulate hepatic TRP metabolism? We found no differences in mRNA levels for KYNA pathway enzymes in the liver ( Figure S4D ) of TAM-treated Egln1 F/F ;HSA-Cre-ER T2 mice compared to control mice. Moreover, serum KYNA was increased 10 min after systemic FG-4497 administration ( Figure 4B ). These two observations suggested that control of KYNA by Egln1 in this model did not involve transcriptional changes in the liver. KYNA production is regulated by KATs (Agudelo et al., 2014 ) that, like Egln1, require aKG as a co-substrate. aKG accumulates under hypoxic conditions and after pVHL loss (with consequent HIF stabilization) (Metallo et al., 2012; Wise et al., 2011) , suggesting that aKG might link Egln1 inactivation to KYNA production. Indeed, aKG levels were elevated in the serum (Figure 4A) , skeletal muscle, and liver in TAM-treated Egln1 F/F ;HSACre-ER T2 mice compared to control mice ( Figure 5B ) and in the livers of mice given FG-4497 compared to vehicle ( Figure 5C ). Systemic administration of aKG, like FG-4497, rapidly (10 min) increased circulating and hepatic KYNA levels ( Figure 5D ). Importantly, systemic aKG administration also protected hearts subjected to I/R injury in vivo ( Figure 5E ) and ex vivo in the Langendorff model ( Figure 5F ). In notable contrast to KYNA, however, aKG did not provide I/R protection when added directly to the perfusate in the Langendorff model ( Figure 5F ), consistent with the idea that aKG protects in vivo by increasing hepatic KYNA production.
HIF-Independent Regulation of aKG Metabolism by Egln1
In cell culture models, hypoxia and FG-4497 both increased aKG levels ( Figures 6A and 6B ). This was true whether aKG levels were normalized to cell number, or to the dioxygenase product succinate (aKG/Suc ratio), or to the transamination partner glutamate (aKG/Glu ratio). FG-4497 had minimal effect on aKG in Egln1 À/À cells, supporting an on-target drug effect ( Figure S5A ).
The rapid induction of aKG ( Figure 5C ) and KYNA ( Figure 4B ) after Egln1 inactivation in vivo suggested that the accumulation of aKG in this setting does not require the canonical Egln1 target HIFa and transcriptional induction of HIF target genes. Consistent with this view, FG-4497 and hypoxia increased the aKG/Glu ratio in Hepa-1c1c7 cells that lack the requisite HIFa transcriptional partner ARNT ( Figure 6C ) and, accordingly, cannot activate a HIF-responsive luciferase reporter after Egln inhibition ( Figure 6D ) despite HIF1a stabilization ( Figure 6E ). Taken together, our data suggest that Egln inhibition in skeletal muscle-in a manner independent of HIF transcriptional activity-increases circulating and hepatic aKG, which drives the production of the cardioprotective metabolite KYNA.
We hypothesized that Egln1 inhibition increases aKG levels as a direct or indirect consequence of altered decarboxylation of its co-substrate, aKG. Egln1 is highly active, with a maximum rate of aKG decarboxylation of 45 mol/mol Egln1/min (Hirsilä et al., 2005) . We estimate that 1 g of skeletal muscle protein contains $ 6.11 pmol of Egln1, which based on the above rate, could decarboxylate 275 pmol aKG/min (Figures S5B-S5F) . As a point of reference, this flux is $0.5% of the skeletal muscle glycolytic rate (Kummitha et al., 2014) .
To assess this predicted high rate of flux further, we traced the conversion of esterified, 13 C-aKG to succinate over time in cells. 13 C-aKG was rapidly converted to 13 C-succinate in both WT (Figure 6F ) and cytochrome B mutant 143B cybrid cells (Figures S5G and S5H) . This conversion was enhanced by ectopic expression of WT, but not catalytically-defective, EGLN1 (Ladroue et al., 2008) , and was decreased by 10-min pretreatment with FG-4497. These effects of manipulating EGLN1 were not due to indirect changes in O 2 consumption because cytochrome B mutant cells lack an intact electron chain and are respiration defective (Sullivan et al., 2015) . These experiments yielded an estimated rate of aKG decarboxylation by EGLN1 of $200 pmol/min/g of tissue ( Figure S5I ). The actual rate might be higher in tissues with high metabolic rates such as the heart, muscle, and liver. Collectively, these findings support a high rate of EGLN1-dependent conversion of aKG to succinate and implicate EGLN1 in the direct control of central carbon metabolism.
DISCUSSION
Cardiovascular diseases such as MI and stroke are the leading cause of death worldwide. Our findings confirm and extend earlier claims that chronic Egln1 inactivation, as well as chronic HIF stabilization, protects the heart against I/R injury (Cai et al., 2008; Hyvä rinen et al., 2010) and permanent ligation injury (Bao et al., 2010; Nwogu et al., 2001 ). However, prolonged HIF activation can ultimately cause deleterious cardiac effects, culminating in dilated cardiomyopathy (Bekeredjian et al., 2010; Huang et al., 2004; Moslehi et al., 2010) . Moreover, these preclinical models of chronic HIF activation do not necessarily address the utility of acutely inactivating Egln1 in the pre-or peri-infarct setting. Using both a conditional Egln1 allele and a small molecule Egln1 inhibitor, we found that acute Egln inactivation protects the heart against I/R injury. Importantly, the use of a pharmacological inhibitor, in contrast to the genetic model, allowed us to model drug treatment at the time of injury, where we again observed significant protection. Nonetheless, EglN1 inhibition might ultimately be most effective when used prophylactically, such as in the setting of unstable angina or elective cardiac surgery, which are associated with a high risk of an ischemic insult.
The cardioprotective effects observed after acute, systemic, Egln1 inactivation are likely to involve both cardiomyocyteintrinsic HIF-dependent effects as well as remote effects. Since Egln1 is ubiquitously expressed and would predictably be inhibited by tissue ischemia, such remote effects could potentially underlie RIPC. Indeed, we found that acute, genetic ablation of Egln1 in skeletal muscles protects the heart at a distance.
We discovered that acute Egln1 inhibition leads to rapid, HIFindependent, systemic induction of aKG, which drives hepatic transamination of the TRP metabolite kynurenine (KYN) to produce KYNA, presumably by stimulating one of several known aKG-dependent KATs. Notably, perivenous hepatocytes are able to utilize circulating aKG to support transamination reactions (Stoll and Hü ssinger, 1989) . KYNA was previously shown to be tissue protective in models of cerebral and renal ischemia (Andiné et al., 1988; Germano et al., 1987; Pundir et al., 2013) . We observed that KYNA is cardioprotective both in vivo and ex vivo and is both necessary and sufficient for remote cardiac protection after skeletal muscle inactivation of Egln1. Although KYNA is critical in our model, additional humoral and neural factors might also contribute to RIPC.
Notably, KYNA is elevated in survivors of cardiac arrest-a condition of systemic ischemia-in both animal models and in humans (Ristagno et al., 2013) . Also, the KYNA precursor, KYN, is induced in hypoxic cells as part of a ''catabolic signature'' of hypoxia (Frezza et al., 2011) . Additionally, the downstream kynurenine pathway metabolite anthranilate is one of the few metabolites elevated for sustained periods after MI, suggesting changes in TRP metabolism during cardiac ischemia (Lewis et al., 2008) . These observations underscore a potential role of TRP metabolism in the response to ischemia.
Our data suggest that acute inactivation of Egln1, which utilizes aKG as a co-substrate, causes the rapid accumulation of aKG. The rate of aKG decarboxylation by EGLN1 is predicted to be high because of the rapid turnover of its hydroxylation targets, the HIFa proteins. Biochemical experiments also suggest that the EGLNs decarboxylate aKG in an uncoupled reaction in the absence of a polypeptide substrate so long as adequate reducing equivalents are available (Hirsilä et al., 2005) , although the relative importance of coupled and uncoupled aKG decarboxylation by the EGLNs in vivo is unknown. Nonetheless, our experiments with 13 C-aKG are consistent with a very high rate of aKG metabolism by EGLN1. Although it is difficult to predict changes in metabolite pool sizes from changes in flux rates, the rapid induction of aKG after Egln1 inhibition is likely due, at least in part, to the abrupt decrease in aKG utilization by Egln1. Notably, acutely inhibiting an aKG flux of nanomoles per minute on a whole mouse basis could theoretically alter serum aKG concentrations in the physiological (mM) range. It is also possible that EGLN1 has a non-canonical substrate that acutely influences aKG pool sizes or that changes in EGLN1 metabolic flux indirectly alter other processes that ultimately impact aKG pool sizes. Finally, decreased aKG uptake by tissues after Egln1 loss might contribute to redistribution of aKG in vivo.
KYNA is an agonist for the aryl hydrocarbon receptor, where it can affect transcription, and a ligand for various receptors including NMDA receptors, neuronal cholinergic a7 nicotine receptors, and the orphan G-coupled receptor GPR35. Interestingly, GPR35 is a HIF target that is induced during cardiac remodeling (Ronkainen et al., 2014) . Clearly additional studies are required to determine how KYNA protects the heart. The mediator(s) of RIPC have been sought for more than 20 years, in hopes they could be used to treat cardiovascular diseases. Two recent large, randomized, studies, however, did not find a benefit of RIPC in patients undergoing cardiac surgery (Hausenloy et al., 2015; Meybohm et al., 2015) . Our findings suggest that the efficacy of RIPC could be influenced by many variables including duration and magnitude of ischemia, skeletal muscle mass, hepatic function, and concurrent medications, including drugs metabolized in the liver, such as anesthetics. With respect to the latter, these two studies required and allowed, respectively, the use of propofol, which has been suggested to block RIPC (Kottenberg et al., 2012 (Kottenberg et al., , 2014 . Direct administration of KYNA might be a more robust way to protect tissues such as the heart than past attempts to induce RIPC with controlled regional ischemia.
EXPERIMENTAL PROCEDURES Materials FG-4497 was obtained from FibroGen and dosed at 50 mg/kg for mouse studies and 30 mM concentration for in vitro studies. 1-Methyl-DL-tryptophan (1-MT) (5 mg/ml) (Sigma-Aldrich) was added to the drinking water of mice.
Cell Culture
Immortalized mouse embryonic fibroblasts (MEFs) were made from Egln1
and Egln1 À/À littermates and maintained in pyruvate-free DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Hepa1c1c7 mouse hepatoma cells (ATCC) were grown in MEM (Corning Mediatech) supplemented with 10% FBS and 1% P/S. 143B cybrid cells (Sullivan et al., 2015) were grown in DMEM supplemented with 10% FBS, 1% P/S, 1 mM sodium pyruvate, and 0.1 mg/ml uridine.
Retroviruses
A Flag-tagged WT human EGLN1 cDNA (Lorenzo et al., 2014) was subcloned into a pLenti vector with a CMV promoter. The H374R mutation (c.1121A / G) was made by site-directed mutagenesis. The 3XHRE luciferase reporter (Yan et al., 2007) was shuttled into a promoterless lentivirus. Lentiviruses were made by co-transfection (TransIT, Mirus Bio) of 293TL cells with expression vectors along with the packaging constructs. Cells were infected by centrifugation in the presence of viral supernatants and polybrene.
Mice
The Egln1 , and ODD-Luc mice were previously described (Minamishima et al., 2008; Moslehi et al., 2010; Safran et al., 2006; Schuler et al., 2005) . Egln1 was deleted by treating age-and sexmatched Egln1 F/F mice harboring a TAM-regulated Cre with TAM 1 mg/dose i.p. For studies in HSA-Cre-ER T2 mice, TAM was given daily for 5 days and mice were studied 5 days later. For studies in Cre ER mice, 3 days of TAM were given and mice were analyzed on day 4 (Minamishima et al., 2008) .
In Vivo Bioluminescence Imaging
In vivo bioluminescence imaging was done as previously described (Safran et al., 2006) . Mice were given FG-4497 (i.p.) at the stated doses 2 hr before D-luciferin (150 mg/kg, i.p.).
Ischemia-Reperfusion Injury
Mice (8-12 weeks old) were anesthetized, intubated, and ventilated. Left thoracotomy was performed, and the left anterior descending (LAD) artery was ligated with a 6.0 silk suture. Ischemia was confirmed by myocardial blanching and electrocardiographic (ECG) evidence of injury. Five minutes into ischemia, 50 ml of fluorescent microspheres (10 mM FluoSpheres, Molecular Probes) was injected into the left ventricular cavity. The LAD ligature was released 30 min later and reperfusion confirmed visually by ECG. Overall survival was 70%-80% at 24 hr. Mice were terminally anesthetized 24 hr after ischemia with ketamine/xylazine followed by cervical dislocation, hearts were harvested, and the ventricles were sectioned from apex to base in 2-mm sections. Sections were incubated in 2% (w/v) triphenyltetrazolium (TTC, Sigma) in phosphate-buffered saline at 25 C for 30 min. Infarct size and area at risk (AAR) was quantified from light and fluorescent micrographs of myocardial sections using Adobe Photoshop. Percent MI was calculated as the infarcted area divided by the AAR. Assessment of I/R injury in the Langendorff Model was as described (Liao et al., 2012) . Parabiosis surgeries were done as per published protocols (Wright et al., 2001) . Ten days after the parabiosis operation, a subset (n = 2) of parabiosed mice was used to confirm the presence of cross-circulation of blood by Evan's Blue dye injection. One mouse in each joined pair was injected with 100 ml of Evan's Blue into the retro-orbital venous plexus. Peripheral blood was collected before and 2 hr after injection. Cardiac I/R injury was performed as described above. The ''recipient'' partner (mouse undergoing I/R) was anesthetized and intubated per protocol while ''donor'' partners was anesthetized using ketamine at 80 mg/kg i.p. for the duration of the surgery.
In Vivo Delivery of Stable Isotope Tracers Conscious, unrestrained mice were infused with 0.19 mg/kg/minute U-13 C-TRP (Cambridge Isotopes Laboratories) in normal saline via a central venous catheter. At 30-min intervals, 20 ml of blood was sampled from an arterial catheter and 10 ml aliquot of plasma was snap-frozen in liquid N 2 . After 90 min, a 50 mg/kg bolus of FG-4497 was dosed over 4 min. Mice were sacrificed by sodium pentobarbital (120 mg/kg) and tissues collected.
Metabolite Extraction and Mass Spectrometry
For metabolic analyses organs were quickly dissected from euthanized mice. Approximately 50 mg tissue sections were clamped between liquid nitrogen-cooled flat forceps, weighed, and ground. Metabolites were extracted in methanol:water:chloroform (6:3:4) by vortexing for 10 min at 4 C followed by centrifugation at 10,000 3 g for 10 min at 4 C. Aliquots of aqueous fractions, in proportion to tissue exact mass, were dried in a refrigerated centrivap. For cell culture experiments, sample extractions were done as described (Fendt et al., 2013 ). For gas chromatography-mass spectrometry (GC-MS) analyses, dried metabolites were derivatized and analyzed as described (Fendt et al., 2013) . Reported are the dominant ions for derivatives of alpha-ketoglutarate (aKG, m/z 346), succinate (Suc, m/z 289), and glutamate (Glu, m/z 432).
13 C mass isotopes were quantified and corrected for natural mass isotope abundances. For liquid chromatography-mass spectrometry (LC-MS) analysis of tissue metabolites, dried metabolites were resuspended in acetonitrile:methanol:formic acid (75:25:0.5 v:v:v) and samples were analyzed in positive and negative ion mode using via hydrophilic interaction liquid chromatography (HILIC) MS analyses (Avanesov et al., 2014; Townsend et al., 2013; Wang et al., 2011) .
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